Metabolic syndrome (MetS) is a multifaceted disorder that impacts approximately 20–25% of the global population. This syndrome encompasses a range of conditions, including obesity, type 2 diabetes ...

Before GLP-1 agonists became the blockbuster obesity drugs many people know and use today, Rhythm Pharmaceuticals was researching molecules that take a similar approach but for a different target. The ...

New research reveals how extracellular matrix (ECM) buildup in the brain’s hypothalamus leads to insulin resistance, paving the way for innovative therapies targeting obesity and diabetes. Study: ...

Imcivree is Rhythm’s only approved drug and the company is now looking forward to an FDA approval for the drug in the treatment of acquired hypothalamic obesity. ・The FDA is expected to rule on the ...

Good morning, everybody. Thank you for joining us today. I'm Dave Connolly, IR here at Rhythm Pharmaceuticals. Before we begin the speaking program, I'll just remind you that this event may include ...